Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




May
15
Today In Oncology
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
FDA Approves Combination Regimen for Newly Diagnosed AML
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo